Analyst Says Sonnet BioTherapeutics Highlighted Encouraging Data For SON-1010 At AACR Meet

Sonnet BioTherapeutics Holdings Inc SONN announced that the safety of SON-1010 dosing has been formally reviewed in both the current Phase 1 clinical trials, and the company is now enrolling the final dose cohort in the cancer trial.
Of the 15 patients from the first five cohorts of SB101 evaluable for follow-up at this latest cutoff, 9 had stable disease at the first follow-up scan, 4 of which were already progressing at study entry.
At four months of follow-up, 5 of 14 patients remained stable at the second scan, suggesting the clinical benefit of SON-1010 in 36% of patients.
The first patient dosed with an aggressive endometrial sarcoma had target tumor shrinkage with complete resolution of ascites at one point and has been clinically stable for nearly a year.
SON-1010 has been safe and tolerable at all doses tested to date, with adverse events generally mild/moderate in intensity and transient.
Chardan Capital maintains a Buy rating on the stock with a price target of $17, down from $22.
Price Action: SONN shares are down 8.97% at $0.30 on the last check Wednesday.

Analyst Calendar